Gabor Boka

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin

Julio Rosenstock, D. Raccah, László Korányi et al. · Diabetes Care · 2013 · 250 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy

Vivian Fonseca, Ricardo Alvarado-Ruiz, D. Raccah et al. · Diabetes Care · 2012 · 218 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Effect of Rimonabant on the High-Triglyceride/ Low–HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat

Jean‐Pierre Després, Robert Ross, Gabor Boka et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2008 · 201 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)

Julio Rosenstock, M Hanefeld, Paramesh Shamanna et al. · Journal of Diabetes and its Complications · 2014 · 126 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13